Tiziana Life Sciences: Foralumab Update in Non-Active Secondary Progressive Multiple Sclerosis (na SPMS)
|DATE:||June 5, 2023|
|TIME:||12:30 PM EDT|
About The Event
Please join Tiziana management and Howard Weiner, MD (Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System) for a discussion of anti-inflammatory approaches in treating neurodegenerative disease which will include an update on the ongoing foralumab Expanded Access program in non-active secondary progressive multiple sclerosis (na SPMS).
The webinar will focus on foralumab, an intranasal fully human monoclonal antibody targeting the CD3 receptor, and its potential for reducing inflammation via modulating the microglia. Foralumab has a novel mechanism of action that increases production of naïve-like T cells and Tregs, while simultaneously decreasing the production of effector T cells.
A live question and answer session will follow the formal presentations.